Allakos Inc. (ALLK) Named Best 2022 Idea a Cowen

Cowen analyst Joseph Thome reiterated an Outperform rating on Allakos Inc. (NASDAQ: ALLK) and named it a Best Idea for 2022.

The analyst commented, "Lirentelimab is approaching two key readouts in patients with eosinophilic gastritis/duodenitis and eosinophilic esophagitis late this year or early next year. While the data event does hold binary risk, Ph. II findings and our consultant checks have been favorable, supporting a positive outcome. Success could solidify lirentelimab's potential in allergic disorders, driving outperformance in 2022."

For an analyst ratings summary and ratings history on Allakos Inc. click here. For more ratings news on Allakos Inc. click here.

Shares of Allakos Inc. closed at $76.29 yesterday.

You May Also Be Interested In

• Cellebrite (CLBT) PT Lowered to $15 at TD Cowen
• STAAR Surgical (STAA) PT Lowered to $28 at Jefferies
• TD Cowen: 'CABA appears well-positioned to scale commercially with minimal capital investment'